MFG
ARQT icon

Merit Financial Group’s Arcutis Biotherapeutics ARQT Stock Holding History

Merit Financial Group’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-18,852
Closed -$444K – 2368
2026
Q1 		$444K Buy
18,852
+5,835
+45% +$149K ﹤0.01% 1437
2025
Q4 		$378K Buy
13,017
+2,952
+29% +$75.6K ﹤0.01% 1444
2025
Q3 		$190K Buy
+10,065
New +$159K ﹤0.01% 1686

Other funds holding ARQT

PL
Perpetual Ltd Sydney, New South Wales, Australia $7B AUM 19.75% 1-Year Est. Return
PCM
Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
AAM
AMI Asset Management Los Angeles, California $1.74B AUM 26.89% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
PR
PSP Research Newtown Square, Pennsylvania $188M AUM
MWS
MFA Wealth Services Thousand Oaks, California $167M AUM 20.54% 1-Year Est. Return
YMRC
Yorktown Management & Research Company Forest, Virginia $163M AUM 68.53% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Merit Financial Group's ARQT Position: Q2 2026 in Review

Merit Financial Group sold out of Arcutis Biotherapeutics (ARQT) in Q2 2026, closing a stake of 18,852 shares — an estimated $444K sold.

Merit Financial Group first reported a position in ARQT in Q3 2025 and held it in 3 quarters. The position peaked at $444K in Q1 2026. 26 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Merit Financial Group reported no remaining Arcutis Biotherapeutics position as of Q2 2026 after selling out during the quarter.
  • Merit Financial Group sold 18,852 Arcutis Biotherapeutics shares in Q2 2026, an estimated $444K.
  • Merit Financial Group first reported a position in Arcutis Biotherapeutics in Q3 2025 and held it in 3 quarters.
  • Merit Financial Group's Arcutis Biotherapeutics position peaked at $444K in Q1 2026.
  • 26 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Merit Financial Group's 13F filing for Q2 2026, filed 17 Jul 2026.